Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety
Authors:
- Kalpana NagpalKNKalpana Nagpal
- S.K. SinghSSS.K. Singh
- D.N. MishraDMD.N. Mishra
- 1 August 2013
- journal article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 59, 72-83
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier ModelPLOS ONE, 2012
- Kinetics of transport of doxorubicin bound to nanoparticles across the blood–brain barrierJournal of Controlled Release, 2011
- Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studiesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2010
- The formulation, characterization andin vivoevaluation of a magnetic carrier for brain delivery of NIR dyeNanotechnology, 2010
- Anaesthetics and postoperative cognitive dysfunction: a pathological mechanism mimicking Alzheimer’s diseaseAnaesthesia, 2010
- Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neuronesJournal of Controlled Release, 2009
- Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activityJournal of Natural Medicines, 2009
- Delivery of nanoparticles to the brain detected by fluorescence microscopyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicityInternational Journal of Pharmaceutics, 2007
- Blood–brain barrier deliveryDrug Discovery Today, 2007